natgillin/translations-raw huggingface dataset:
For more information about treatment with Zavicefta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Zavicefta preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with Zavicefta? 
Kakšna tveganja so povezana z zdravilom Zavicefta?
However, the CHMP considered that the data already available supported Zavicefta's activity in hospital-acquired pneumonia and for the treatment of infections due to aerobic Gram-negative organisms in adult patients when other treatments might not work. 
Vendar pa je odbor CHMP menil, da razpoložljivi podatki podpirajo učinkovitost zdravila Zavicefta pri bolnišnični pljučnici in za zdravljenje okužb zaradi aerobnih gramnegativnih organizmov pri odraslih bolnikih, kadar druge oblike zdravljenja niso učinkovite.
In two studies, the effects of the combination of Zavicefta and metronidazole (another antibiotic) were compared with those of the antibiotic meropenem in 1490 patients with complicated intra-abdominal infection. 
V dveh študijah so učinke kombinacije zdravila Zavicefta in metronidazola (drugega antibiotika) primerjali z učinki antibiotika meropenema pri 1 490 bolnikih z zapleteno intraabdominalno okužbo.
The company that makes Zavicefta is carrying out a study to compare the effectiveness and safety of Zavicefta with meropenem (another antibiotic) for the treatment of hospital-acquired pneumonia. 
Družba, ki izdeluje zdravilo Zavicefta, izvaja študijo primerjave učinkovitosti in varnosti zdravila Zavicefta z meropenemom (drugim antibiotikom) pri zdravljenju bolnišnične pljučnice.
Zavicefta must not be used in patients who are hypersensitive (allergic) to the active substances in Zavicefta or any of the other ingredients, or in those who are hypersensitive to other cephalosporin antibiotics or have ever had a severe allergic reaction to another beta-lactam antibiotic. 
Zdravilo Zavicefta se ne sme uporabljati pri bolnikih, ki so preobčutljivi za (alergični na) zdravilni učinkovini zdravila Zavicefta ali katero koli sestavino zdravila, ter pri tistih, ki so preobčutljivi za druge cefalosporinske antibiotike ali ki so kdaj imeli hudo alergijsko reakcijo na drug betalaktamski antibiotik.
• complicated (difficult to treat) infections of the tissues and organs within the belly (intra-abdominal infections); 
• zapletenih (težko ozdravljivih) okužb tkiv in organov v trebušnem predelu (intraabdominalnih okužb);
The most common side effects with Zavicefta (which affected more than 5 in 100 people) are nausea (feeling sick), diarrhoea and a positive result in a Coombs test (a sign of the development of antibodies that attack red blood cells). 
Najpogostejši neželeni učinki zdravila Zavicefta (ki lahko prizadenejo več kot 5 oseb od 100) so navzeja (slabost), driska in pozitiven rezultat na Coombsovem testu (znak nastanka protiteles, ki napadejo rdeče krvničke).
Regarding Zavicefta's safety profile, side effects were those that can be expected for ceftazidime and a betalactamase inhibitor. 
Kar zadeva varnostni profil zdravila Zavicefta, so neželeni učinki taki, kot jih je mogoče pričakovati pri ceftazidimu in zaviralcu betalaktamaze.
This causes weakness in the bacterial cell walls which then become prone to collapse, ultimately leading to the death of the bacteria. 
S tem povzroči šibkost bakterijskih celičnih sten, ki zato pogosto propadejo, zaradi česar bakterije sčasoma odmrejo.
Why is Zavicefta approved? 
Zakaj je bilo zdravilo Zavicefta odobreno?
What benefits of Zavicefta have been shown in studies? 
Kakšne koristi je zdravilo Zavicefta izkazalo v študijah?
By blocking the action of these enzymes, avibactam allows ceftazidime to act against bacteria that would otherwise be resistant. 
Avibaktam z zaviranjem delovanja teh encimov omogoča ceftazidimu, da učinkovito deluje proti bakterijam, ki bi sicer bile odporne.
A third study looked at 332 patients with complicated intra-abdominal or urinary tract infections caused by Gram-negative bacteria that were resistant to ceftazidime (could not be killed by ceftazidime). 
V tretji študiji so proučevali 332 bolnikov z zapletenimi intraabdominalnimi okužbami ali okužbami sečil zaradi gramnegativnih bakterij, ki so odporne proti ceftazidimu (ki jih ni bilo mogoče uničiti s ceftazidimom).
Ceftazidime is an antibiotic called a cephalosporin, which belongs to the wider group ‘beta-lactams'. 
Ceftazidim je antibiotik, imenovan cefalosporin, ki spada v širšo skupino betalaktamov.
Zavicefta can only be obtained with a prescription, and prescribers should take into account official guidance on the use of antibiotics. 
Izdaja zdravila Zavicefta je le na recept, poleg tega morajo zdravniki, ki zdravilo predpisujejo, upoštevati uradne smernice za uporabo antibiotikov.
Both studies showed that Zavicefta in combination with metronidazole was at least as effective as meropenem at curing the infection. 
Obe študiji sta pokazali, da je bilo zdravilo Zavicefta v kombinaciji z metronidazolom pri zdravljenju okužb vsaj tako učinkovito kot meropenem.
For practical information about using Zavicefta, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Zavicefta naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
These enzymes enable bacteria to break down beta-lactam antibiotics such as ceftazidime, making them resistant to the antibiotic's action. 
Ti encimi bakterijam omogočajo, da razgrajujejo betalaktamske antibiotike, kot je ceftazidim, in posledično postanejo odporne proti njihovemu delovanju.
In a fourth study, 1,020 patients with complicated urinary tract infections (including pyelonephritis) caused by Gram-negative bacteria were treated with Zavicefta or the antibiotic doripenem. 
V četrti študiji je bilo 1 020 bolnikov z zapletenimi okužbami sečil (vključno s pielonefritisom) zaradi gramnegativnih bakterij zdravljenih z zdravilom Zavicefta ali antibiotikom doripenemom.
Zavicefta is available as a powder to be made up into a solution for infusion (drip) into a vein. 
Zdravilo Zavicefta je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
Zavicefta was at least as effective as doripenem: 77% of patients (304 out of 393) treated with Zavicefta showed a response compared with 71% of patients (296 out of 417) treated with doripenem. 
Zdravilo Zavicefta je bilo vsaj tako učinkovito kot doripenem: pri 77 % (304 od 393) bolnikov, zdravljenih z zdravilom Zavicefta, je bil opazen odziv v primerjavi z 71 % (296 od 417) bolnikov, zdravljenih z doripenemom.
Zavicefta alone (for urinary tract infection) or in combination with metronidazole (for intra-abdominal infection) provided similar results to a number of alternative antibiotics in curing the infection: 91% of patients (140 out of 154) were cured after treatment with Zavicefta compared with 91% (135 out of 148) after treatment with the best alternative antibiotic. 
Pri samostojni uporabi zdravila Zavicefta (za zdravljenje okužb sečil) ali v kombinaciji z metronidazolom (za zdravljenje intraabdominalnih okužb) so bili rezultati podobni kot pri številnih nadomestnih antibiotikih, ki se uporabljajo za zdravljenje okužb: 91 % (140 od 154) bolnikov je bilo ozdravljenih po zdravljenju z zdravilom Zavicefta v primerjavi z 91 % (135 od 148) bolnikov, zdravljenih z najboljšim nadomestnim antibiotikom.
The CHMP considered that the studies on Zavicefta show that is effective at treating complicated intra-abdominal and urinary tract infections. 
Menil je, da študije zdravila Zavicefta kažejo, da je to zdravilo učinkovito pri zdravljenju zapletenih intraabdominalnih okužb in okužb sečil.
In addition, disease-causing bacteria were eliminated in 82% (126 out of 154) of patients after treatment with Zavicefta compared with 63% (94 out of 148) after treatment with the best alternative antibiotic. 
Poleg tega so bile bakterije, ki povzročajo bolezen, izkoreninjene pri 82 % (126 od 154) bolnikov po zdravljenju z zdravilom Zavicefta v primerjavi s 63 % (94 od 148) bolnikov, zdravljenih z najboljšim nadomestnih antibiotikom.
For the full list of all side effects with Zavicefta, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Zavicefta, glejte navodilo za uporabo.
• complicated (difficult to treat) infections of the urinary tract (structures that carry urine), including pyelonephritis (kidney infection); 
• zapletenih (težko ozdravljivih) okužb sečil (struktur za odvajanje urina), vključno s pielonefritisom
In the second study, 94% of patients (166 out of 177) treated with Zavicefta and metronidazole were cured, compared with 94% (173 out of 184) of patients treated with meropenem. 
V drugi študiji je bilo ozdravljenih 94 % (166 od 177) bolnikov, ki so se zdravili z zdravilom Zavicefta in metronidazolom, v primerjavi s 94 % (173 od 184) bolnikov, ki so se zdravili z meropenemom.
How is Zavicefta used? 
Kako se zdravilo Zavicefta uporablja?
Avibactam blocks the action of bacterial enzymes called beta-lactamases. 
Avibaktam zavira delovanje bakterijskih encimov, imenovanih betalaktamaze.
In the first study, one of the patient groups studied showed 92% of patients (376 out of 410) treated with Zavicefta and metronidazole were cured, compared with 93% (385 out of 416) of patients treated with meropenem. 
V prvi študiji je bilo v eni od skupin bolnikov ozdravljenih 92 % (376 od 410) bolnikov, ki so se zdravili z zdravilom Zavicefta in metronidazolom, v primerjavi s 93 % (385 od 416) bolnikov, ki so se zdravili z meropenemom.
The active substances in Zavicefta are ceftazidime and avibactam. 
Zdravilni učinkovini v zdravilu Zavicefta sta ceftazidim in avibaktam.
How does Zavicefta work? 
Kako zdravilo Zavicefta deluje?
Zavicefta contains the active substances ceftazidime and avibactam. 
Zdravilo Zavicefta vsebuje zdravilni učinkovini ceftazidim in avibaktam.
International non-proprietary name (INN): abetimus 
Mednarodno nelastniško ime (INN): abetimus
London, 18 October 2006 Doc. 
London, 18. oktober 2006 Sklic dok.
The Company has no compassionate use programme. 
Podjetje ne izvaja programa sočutne uporabe.
The letter from the company notifying the EMEA of the withdrawal of the application is available here. 
Dopis podjetja, v katerem obvešča agencijo EMEA o umiku svoje vloge, je na voljo tukaj.
A compassionate use programme is a programme through which doctors can request a medicine for a specific disease for one of their patients before the medicine is fully authorised. 
Program sočutne uporabe je program, ki omogoča zdravnikom, da zaprosijo za zdravilo za določeno bolezen za katerega od svojih bolnikov, še preden je zdravilo v celoti odobreno.
If you are in a clinical trial and need more information about your treatment, contact the doctor who is giving it to you. 
Če sodelujete v kliničnem preizkušanju in potrebujete več informacij o svojem zdravljenju, se obrnite na zdravnika, ki vam je zdravilo predpisal.
Ref. EMEA/410799/2006 
EMEA/435970/2006
The effects of Riquent were first tested in experimental models before being studied in humans. 
Učinki zdravila Riquent so bili najprej raziskani v izkustvenih modelih, šele potem so bili preizkušeni na ljudeh.
QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for RIQUENT 
VPRAŠANJA IN ODGOVORI GLEDE UMIKA VLOGE ZA IZDAJO DOVOLJENJA ZA PROMET za zdravilo RIQUENT
What are the consequences of the withdrawal for patients undergoing clinical trials / compassionate use programmes with Riquent? 
Kakšne so posledice umika za bolnike, ki sodelujejo v kliničnih preizkušanjih/programih sočutne uporabe zdravila Riquent?
Riquent is a solution for injection that contains 50 mg/ml of the active substance abetimus. 
Zdravilo Riquent je raztopina za injiciranje, ki vsebuje 50 mg/ml zdravilne učinkovine abetimus.
Abetimus is a small piece of double-stranded DNA that has been designed to reduce circulating levels of these antibodies. 
Abetimus je delček dvoverižne DNA, razvit za zmanjšanje stopnje cirkulacije teh protiteles.
The CHMP was evaluating the initial documentation provided by the Company and had not yet made any recommendations. 
CHMP je takrat ocenjeval začetno dokumentacijo, ki jo je posredovalo podjetje, in še ni podal nikakršnih priporočil.
On 13 October 2006, La Jolla Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Riquent, for the treatment of lupus nephritis. 
Podjetje La Jolla Limited je dne 13. oktobra 2006 obvestilo Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za izdajo dovoljenja za promet z zdravilom Riquent, namenjenim za zdravljenje lupusnega nefritisa.
The company informed the CHMP that it plans to continue the ongoing clinical trials in the treatment of lupus nephritis. 
Podjetje je CHMP obvestilo, da namerava nadaljevati s potekajočimi kliničnimi preizkušanji zdravljenja lupusnega nefritisa.
When Riquent is injected, the levels of these antibodies in the blood are lowered and this is expected to help reduce the patient's likelihood of experiencing a ‘flare'. 
Če se vbrizga zdravilo Riquent, se raven teh protiteles v krvi zmanjša in to bi naj prispevalo k zmanjšanju verjetnosti, da bolnik doživi pojav širjenja obolenja.
Because the number of patients with lupus nephritis is low, the disease is rare, and Riquent was designated an orphan medicine (a medicine used in rare diseases) on 20 November 2001. 
Ker je število bolnikov z lupusnim nefritisom majhno, je ta bolezen redka, zato je bilo zdravilo Riquent 20. novembra 2001 določeno kot »zdravilo sirota« (zdravilo, ki se uporablja pri redkih boleznih).
Abetimus, the active substance in Riquent, is a selective immunosuppressive agent (a compound that selectively dampens down the immune system). 
Abetimus, zdravilna učinkovina v zdravilu Riquent, je selektivna imunosupresivna učinkovina (spojina, ki selektivno pomirja imunski sistem).
There were two main studies involving a total of 529 patients with SLE, in which Riquent was compared with a placebo (a dummy treatment). 
Izvedeni sta bili dve glavni raziskavi, ki sta vključevali 529 bolnikov s sistemskim eritematoznim lupusom, pri katerih so zdravilo Riquent primerjali s placebom (zdravilom brez zdravilne učinkovine).
The studies measured how many patients developed ‘flares' and the time to the development of the flares by measuring the levels of protein in the urine and of creatinine (an enzyme that is a marker of kidney function) in the blood. 
Raziskavi sta merili, pri koliko bolnikih se je razvil pojav širjenja obolenja, in čas do razvoja tega pojava z merjenjem ravni beljakovin v urinu in kreatinina (encima, ki je marker delovanja ledvic).
The application was at day 114 when the company withdrew. 
Podjetje je vlogo umaknilo na 114. dan postopka.
What was Riquent expected to be used for? 
Za kaj naj bi se zdravilo Riquent uporabljalo?
Most patients with SLE have antibodies in their blood that are directed against double-stranded DNA (deoxyribonucleic acid). 
Večina bolnikov s sistemskim eritematoznim lupusom ima v krvi protitelesa, ki so usmerjena proti dvoverižni DNA (deoksiribonukleinski kislini).
Once the company has supplied responses to the questions, the CHMP reviews them and may, before giving an opinion, ask any remaining questions at day 180. 
Ko podjetje pripravi odgovore na vprašanja, jih CHMP pregleda in pred izdajo mnenja lahko zaprosi podjetje še za
These antibodies are thought to be linked to the development of lupus kidney disease. 
Ta protitelesa naj bi bila po predvidevanjih povezana z razvojem lupusne ledvične bolezni.
Riquent was expected to delay and to reduce the incidence of ‘flares' (increased signs of kidney disease). 
Zdravilo Riquent bi naj zavrlo in zmanjšalo pogostost pojava širjenja obolenja (povečanih znakov ledvične bolezni).
What is Riquent? 
Kaj je zdravilo Riquent?
Riquent was expected to be used to treat lupus nephritis, an inflammation of the kidneys in patients with systemic lupus erythematosus (SLE, an auto-immune disease caused by the body's own defence system attacking normal tissue) who have a history of kidney disease and have been tested to check that they will benefit from the medicine. 
vnetja ledvic pri bolnikih s sistemskim eritematoznim lupusom (SLE, avtoimunsko boleznijo, pri kateri obrambni sistem telesa napade normalna tkiva), ki so imeli v preteklosti ledvično bolezen in so bili testirani z namenom ugotoviti, ali bi jim lahko zdravilo pomagalo.
How is Riquent expected to work? 
Kako naj bi zdravilo Riquent delovalo?
The European Commission granted a marketing authorisation valid throughout the European Union for Caelyx on 21 June 1996. 
Evropska komisija je dovoljenje za promet z zdravilom Caelyx, veljavno po vsej Evropski uniji, odobrila dne 21. junija 1996.
The marketing authorisation holder is Janssen-Cilag International NV. 
Imetnik dovoljenja za promet z zdravilom je družba Janssen-Cilag International NV.
It works by interfering with the DNA within cells, preventing them from making more copies of DNA and making proteins. 
Deluje tako, da zavira DNK v celicah in jim tako preprečuje tvorjenje novih kopij DNK in proizvajanje beljakovin.
Doxorubicin hydrochloride has been available since the 1960s. 
Doksorubicinijev klorid je na voljo od šestdesetih let prejšnjega stoletja.
The full EPAR for Caelyx can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Caelyx je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This means that cancer cells cannot divide and eventually die. 
To pomeni, da se celice raka ne morejo razmnoževati in sčasoma odmrejo.
The most common side effect seen in all types of cancer (in more than 1 patient in 10) is nausea (feeling sick). 
Najpogostejši neželeni učinek, opažen pri vseh oblikah raka (pri več kot 1 bolniku izmed 10), je navzeja (slabost).
It also reduces its effects on non-cancer tissues and cells, so it is less likely to cause some side effects. 
Prav tako zmanjša učinke zdravila na nerakava tkiva in celice, zato je verjetnost, da povzroči določene neželene učinke, manjša.
This is a summary of the European public assessment report (EPAR) for Caelyx. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Caelyx.
The main measure of effectiveness was time until the disease got worse or, for Kaposi's sarcoma, the number of patients who responded to treatment. 
Glavno merilo učinkovitosti je bil čas do poslabšanja bolezni, pri Kaposijevem sarkomu pa število bolnikov, ki so se odzvali na zdravljenje.
For more information about treatment with Caelyx, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Caelyx preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
It contains the active substance doxorubicin hydrochloride (2 mg/ml). 
Vsebuje zdravilno učinkovino doksorubicinijev klorid (2 mg/ml).
For Kaposi's sarcoma, around 70% of the patients had a complete or partial response to treatment, with similar results in the study of patients who had been treated before. 
Pri zdravljenju Kaposijevega sarkoma se je približno 70 % bolnikov popolnoma ali delno odzvalo na zdravljenje, podobni rezultati pa so bili doseženi tudi v študiji z bolniki, ki so se že prej zdravili.
It cannot be interchanged with other medicines containing doxorubicin hydrochloride. 
Ne sme se zamenjevati z drugimi zdravili, ki vsebujejo doksorubicinijev klorid.
Caelyx is used to treat the following types of cancer in adults: 
Zdravilo Caelyx se uporablja za zdravljenje naslednjih vrst raka pri odraslih:
The additional studies showed that Caelyx was also more effective than the comparator combinations. 
Dodatne študije so pokazale, da je zdravilo Caelyx učinkovitejše od primerjanih kombinacij.
Caelyx doxorubicin hydrochloride 
Caelyx doksorubicinijev klorid
Other very common side effects include palmar-plantar erythrodysaesthesia syndrome (redness and pain on the hands and feet), vomiting, stomatitis (inflammation of the lining of the mouth), rash, asthenia (weakness), low blood cell counts, loss of appetite, alopecia (hair loss), fatigue (tiredness), diarrhoea, constipation and mucositis (inflammation of the mouth and throat). 
Drugi zelo pogosti neželeni učinki so sindrom palmarno-plantarne eritrodisestezije (pordelost in bolečine na dlaneh in stopalih), bruhanje, stomatitis (vnetje ustne sluznice), izpuščaj, astenija (šibkost), nizka raven krvnih celic, izguba teka, alopecija (izpadanje las), utrujenost, driska, zaprtost in mukozitis (vnetje v ustih in žrelu).
• metastatic breast cancer in patients at risk of heart problems. 
• metastatskega raka dojk pri bolnikih s povečanim tveganjem za nastanek bolezni srca.
For Kaposi's sarcoma, the dose is 20 mg/m2 every two to three weeks for two to three months, and for multiple myeloma, it is 30 mg/m2 on day four of each three-week cycle of bortezomib treatment, for as long as the patient continues to benefit from the treatment and can tolerate it. 
Za Kaposijev sarkom je odmerek 20 mg/m2 na vsaka dva do tri tedne v skupnem trajanju dva do tri mesece, za multipli mielom pa je odmerek 30 mg/m2 na četrti dan vsakega tritedenskega cikla zdravljenja z bortezomibom tako dolgo, dokler bolniku zdravljenje koristi in ga dobro prenaša.
However, patients receiving Caelyx were less likely to experience heart problems. 
Vendar je bila pri bolnikih, ki so prejemali zdravilo Caelyx, verjetnost težav s srcem manjša.
Further studies compared Caelyx with the combination of doxorubicin, bleomycin and vincristine (other anticancer medicines) in 258 patients and with the combination of bleomycin and vincristine in 241 patients. 
V dodatnih študijah so zdravilo Caelyx primerjali s kombinacijo doksorubicina, bleomicina in vinkristina (drugih zdravil proti raku) pri 258 bolnikih ter s kombinacijo bleomicina in vinkristina pri 241 bolnikih.
Caelyx is used in combination with bortezomib (another anticancer medicine). 
Zdravilo Caelyx se uporablja v kombinaciji z bortezomibom (drugim zdravilom proti raku).
What benefit has Caelyx shown during the studies? 
Kakšne koristi je zdravilo Caelyx izkazalo med študijami?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Caelyx. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Caelyx, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Caelyx must not be used to treat Kaposi's sarcoma that could be treated effectively with ‘local' treatments that only affect the site of the tumour or with whole-body alfa interferon treatment. 
Zdravilo Caelyx se ne sme uporabljati za zdravljenje Kaposijevega sarkoma, ki bi ga bilo mogoče učinkovito zdraviti „lokalno“ z zdravili, ki delujejo le na mesto tumorja, ali z interferonom alfa, ki deluje na celotno telo.
The recommended starting dose of Caelyx for breast or ovarian cancer is 50 mg per square metre body surface area (calculated using the patient's height and weight) every four weeks for as long as the disease does not get worse and the patient can tolerate the treatment. 
Priporočeni začetni odmerek zdravila Caelyx za zdravljenje raka dojk in raka jajčnikov je 50 mg na kvadratni meter telesne površine (ki se izračuna na podlagi telesne višine in mase bolnika) enkrat na vsake štiri tedne, dokler se bolezen ne poslabša in bolnik dobro prenaša zdravljenje.